Brief: Gossamer Bio Q2 EPS USD -0.45
08/08/2023 21:01
Aug 08 (Reuters) - Gossamer Bio Q2 net income USD -42.496 million
Recent news on Gossamer Bio
See all newsBrief: Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Gossamer Bio - Board Approves Amendment And Restatement Of Bylaws Effective Sept 3, 2026 - SEC Filing